Yonsei Med J.
2004 Jun;45(3):435-442. 10.3349/ymj.2004.45.3.435.
Retinoic Acid Receptor-beta Expression in Stage I Non-Small Cell Lung Cancer and Adjacent Normal Appearing Bronchial Epithelium
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. sekyukim@yumc.yonsei.ac.kr.
- 2Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
- 3Department of Cardiovascular and Thoracic Surgery, Yonsei University College of Medicine, Seoul, Korea.
- 4The Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea.
- 5Brain Korea 21 Project for Medical Science, Korea.
- 6Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.
- 7Department of Internal Medicine, Kwandong University College of Medicine, Myungji Hospital, Koyang, Korea.
- KMID: 1734125
- DOI: http://doi.org/10.3349/ymj.2004.45.3.435
Abstract
- Retinoic acid receptor- (RAR-beta) is induced by and mediates the growth-inhibitory and apoptotic effects of retinoic acid (RA), suggesting that loss of RAR-betaexpression may be one of the critical events involved in the carcinogenesis/ progression of non-small cell lung cancer (NSCLC) and in the responsiveness to retinoid chemotherapy. However, recent contradictory reports that the expression of RAR-beta is associated with poor clinical outcome, and the fact that treatment of serum-deprived type 2 alveolar cells with RA leads to a stimulation of cell proliferation, require the verification of RAR-beta as a biomarker of chemoprevention or prognosis. The expression status of RAR-beta in cancer cells and adjacent normal appearing bronchial epithelium from 39 patients, diagnosed as stage I NSCLC and undergone a curative lung resection, was analyzed in paraffin-embedded tissue sections by IHC staining. The normal appearing bronchial epithelium of 14 out of 33 (42.4%) specimens expressed RAR-beta, whereas 22 out of the 39 (56.4%) stage I NSCLC specimens expressed RAR-beta. RAR-beta was more frequently expressed in the adenocarcinoma (72.7%) than in the squamous cell carcinoma (31.3%) (p=0.026). Neither the expression status in normal appearing adjacent tissue nor that in the tumor tissue had prognostic implications. The higher expression of RAR-beta in cancer tissue, the focal and uneven distribution in normal appearing adjacent bronchial epithelium, and inconsistency with the corresponding tumor tissue, suggest that the expression status of RAR-beta as a biomarker for chemoprevention/early diagnosis or the prognosis of NSCLC requires further consideration.
Keyword
MeSH Terms
-
Adult
Aged
Bronchi/metabolism/pathology
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology
Down-Regulation
Female
Human
Immunohistochemistry
Lung Neoplasms/*metabolism/pathology
Male
Middle Aged
Neoplasm Staging
Receptors, Retinoic Acid/*metabolism
Respiratory Mucosa/*pathology
Tumor Markers, Biological/*metabolism
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Expression of TGF-beta1 and TGF-beta Receptor I in Human Lung Cancer
- Combinational Treatment with Retinoic Acid Derivatives in Non-small Cell Lung Carcinoma In Vitro
- Effects of Retinoic Acid on the Cell Proliferating Activity and the Expression of Fibroblast Growth Factor 2, Fibroblast Growth Factor Receptor 2 during Palatal Development of Mice
- Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer
- The Effect of Intravitreal Injection of Retinoic Acid on Experimentally Induced Proliferative Vitreoretinopathy using Human Retinal Prgment Epithelium in Rabbits
